a 2 × 105 strongly acidic tumor cells (B16F10) were inoculated into the right flank of Gpr65-deficient ...
Study design, patient eligibility and treatment This was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation ...
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global ...
Fenis, A., Demaria, O., Gauthier, L., Vivier, E. & Narni-Mancinelli, E. New immune cell engagers ...
Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer ...
Construction and characterization of the bispecific cell engager MSLN×CD16A To construct the bispecific cell engager ...